news
blogs
Poster Prize awardees at the Biochemical Society conference in Edinburgh.
We congratulate the Poster Prize awardees at last week's Deubiquitylases and Ubl-proteases conference of the Biochemical Society in Edinburgh!
Moving our offices & laboratories.
We are happy and proud to announce that we have moved our office and labs to a brand new building at Science Park 301, just a five minutes walk from our old laboratories in the...
Launch of an activity-based probe designed to selectively target USP7.
We hereby announce the launch of an activity-based probe that is designed to selectively target USP7: K58K(biotin) cRh110-Cys-Ubv(USP7)-PA (UbiQ-314). UbiQ-314 is based on Ub with the following mutations: T7D, L8Y, I13R, E34L, Q40N, L69A, and L71A....
Public-private partnership grant awarded by Health-Holland: Towards new drug therapies by a better understanding of ubiquitin metalloprotease activity.
We are happy to announce that UbiQ and Prof Titia Sixma (Netherlands Cancer Institute, Oncode Institute) were recently awarded a new public-private partnership grant by Health-Holland, which is part of the Dutch Life Sciences &...
Reagents for your SARS-CoV-2 research
Reagents for your SARS-CoV-2 research The SARS-CoV-2 coronavirus encodes a papain-like cysteine protease PLpro (NSP3) that cleaves the viral polyprotein, removes ubiquitin-like ISG15 protein modifications and (with lower activity) Lys48-linked polyubiquitin chains. As PLPro is essential for SARS-CoV-2 replication, it represents a promising target for the...
In memoriam: Professor Huib Ovaa
On the 19th of May 2020, our co-founder and dear friend Professor Dr. Huib Ovaa passed away from prostate cancer at the age of 46 years. In the past year, Huib has undergone a variety...
Public-private partnership grant by Health-Holland: New drug therapies by a better understanding of ubiquitin metalloprotease activity Tools to study ubiquitin metalloprotease activity.
17 December 2019 Public-private partnership grant awarded by Health-Holland We are happy to announce that UbiQ and Prof Titia Sixma (Netherlands Cancer Institute, Netherlands) were recently awarded a public-private partnership grant...
where to meet us
EMBO conference on Ubiquitin 2024
September 27 - October 1, 2024 Cavtat, Croatia Ubiquitin and ubiquitin-like proteins in health and disease. Contact: Alfred Nijkerk (CEO)
2nd Severo Ochoa Conference: Ligating the Ubiquitin Family; Physiology, Disease, and Future Directions June 2024
June 24 - 25, 2024 Bilbao, Spain 2nd Severo Ochoa Conference: Ligating the Ubiquitin Family; Physiology, Disease, and Future Directions June 2024 Contact: Farid El Oualid (CSO) (sponsorship)
Ubiquitin & Friends Symposium May 2024
May 2 - 3, 2024 Vienna, Austria Ubiquitin & Friends Symposium May 2024 Contact: Farid El Oualid (CSO) (sponsorship)
BIO-Europe Spring 2024
UbiQ will attend BIO-Europe Spring. March 17 - 20, 2024 Barcelona, Spain Contact: Alfred Nijkerk BIO-Europe: https://informaconnect.com/bioeurope-spring/
Biochemical Society: Deubiquitylases and Ubl-proteases, from fundamental principles to therapeutic opportunities 2023
June 19 - 21, 2023 Edinburgh, UK Deubiquitylases and Ubl-proteases: from fundamental principles to therapeutic opportunities 2023. Contact: Farid El Oualid (CSO)
Ubiquitin & Friends Symposium April 2023
April 27 - 28, 2023 Vienna, Austria Ubiquitin & Friends Symposium April 2023 Contact: Farid El Oualid (CSO) (sponsorship)
Ubiquitin-NL 2023 symposium
May 22, 2023 Leiden, NL Ubiquitin-NL 2023 symposium. Contact: Alfred Nijkerk (CEO)
publications
Characterization of the Ubiquitin and ISG15 Deconjugase Activity of SARS-CoV-1 and SARS-CoV-2 Papain-Like Protease.
UbiQ is proud to have contributed a chapter to the Methods in Molecular Biology book series (MIMB,volume 2591), together with the Department of Biochemistry & Structural Biology, University of Texas Health Science Center at San...
Catalytic and regulatory mechanisms of the dual-specificity ubiquitin/FAT10 E1 enzyme Uba6.
UbiQ is proud to have been part of a major collaborative research project focused on studying the dual-specificity ubiquitin/FAT10 E1 enzyme Uba6 and whose results have been reported recently in Nature Communications. Yuan et al. Crystal...
Collaborative research between the University of York, University of Glasgow and UbiQ looks into the (essential) roles of ubiquitin proteases (DUBs) and ubiquitin conjugation in Leishmania parasites.
21st Royal Society of Chemistry - Medicinal Chemistry Symposium, 13 - 15 September 2021, Cambridge UK. Poster title: A ubiquitin activating enzyme as a novel therapeutic target for leishmaniasis. Daniel Harris (1), Dr Mads Gabrielson (2), Dr...
Anti–COVID-19 Drug Design by targeting a molecular scissor of Ubiquitin and ISG15.
UbiQ is proud to have been part of a major collaboration reported recently by Rut et al. in Science Advances, describing the activity profiling and crystal structures of inhibitor bound SARS-CoV-2 PLpro: Activity profiling and crystal...
Leishmania differentiation requires ubiquitin conjugation mediated by a UBC2-UEV1 E2 complex.
Collaborative research between the University of York, University of Glasgow and UbiQ looks into the (essential) roles of ubiquitin proteases (DUBs) and ubiquitin conjugation in Leishmania parasites. Leishmaniasis is a neglected tropical disease caused by parasites...
Strategy for Development of Site-Specific Ubiquitin Antibodies.
As part of collaborative research between The Netherlands Cancer Institute, Leiden University Medical Centre, UbiQ and the University of Amsterdam, van Kruijsbergen et al. report in Frontiers in Chemistry detailed protocols for the development of...
Diubiquitin-Based NMR Analysis: Interactions Between Lys6-Linked diUb and UBA Domain of UBXN1.
As part of collaborative research carried out by The Netherlands Cancer Institute, Leiden University Medical Centre, Utrecht University, UbiQ and the University of Cologne, Hameed et al. report in Frontiers in Chemistry the synthesis of...